Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Aytu BioPharma (NASDAQ:AYTU – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Cocrystal Pharma and Aytu BioPharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
| Aytu BioPharma | 2 | 0 | 2 | 0 | 2.00 |
Aytu BioPharma has a consensus price target of $14.50, suggesting a potential upside of 696.70%. Given Aytu BioPharma’s higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Cocrystal Pharma.
Institutional and Insider Ownership
Risk and Volatility
Cocrystal Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
Profitability
This table compares Cocrystal Pharma and Aytu BioPharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -207.47% | -123.33% |
| Aytu BioPharma | -24.76% | -56.54% | -13.14% |
Earnings & Valuation
This table compares Cocrystal Pharma and Aytu BioPharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | $330,000.00 | 57.07 | -$8.83 million | ($0.76) | -1.29 |
| Aytu BioPharma | $57.57 million | 0.34 | -$14.25 million | ($1.66) | -1.10 |
Cocrystal Pharma has higher earnings, but lower revenue than Aytu BioPharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.
Summary
Aytu BioPharma beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
About Aytu BioPharma
Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions. The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
